CA 15-3 Blood Test: Normal Range, High Levels & Breast Cancer

The CA 15-3 blood test (cancer antigen 15-3) in breast cancer: normal range in U/mL, what a high CA 15-3 means, benign causes, and why it is not a screening test.

Published July 18, 202612 min readWritten by the Blood Analysis Team · Reviewed and verified by Julien Priour

The CA 15-3 blood test measures cancer antigen 15-3, a protein fragment shed into the blood that is used mainly to monitor breast cancer — chiefly in advanced or metastatic disease. It is a tumor marker, not a cancer test: a high CA 15-3 is never, on its own, a diagnosis of cancer, and a normal CA 15-3 does not rule disease out. Many people first meet this number on a lab report and understandably worry. This guide explains, calmly, the normal CA 15-3 range, what a raised value does and does not mean, its benign causes, and why the result is always read by an oncologist — never alone. If you are looking at other markers, see the PSA test or the CA-125 test.

Key takeaways

CA 15-3 is a tumor marker tied mainly to breast cancer. It is used for monitoring, not for screening or diagnosis.¹²³
Indicative normal range: under about 30 U/mL, with labs varying roughly 25–35 U/mL depending on the assay — trust the range printed on your report.⁴⁵
Major U.S. guidance (ASCO) does not recommend CA 15-3 to screen for breast cancer or to routinely follow patients with early-stage disease; its role is mainly in metastatic disease.¹⁶⁷
A mildly high CA 15-3 is often benign: benign breast disease, liver disease, pregnancy and lactation, benign ovarian conditions, or other cancers.⁴⁵
Sensitivity is low in early, localized breast cancer and higher in metastatic disease — a normal value does not exclude cancer.⁸⁹
High CA 15-3 ≠ breast cancer. Only your physician interprets it, alongside imaging and the clinical exam, and the trend over time matters more than a single number.²⁶

Normal CA 15-3 levels

There is no single universal cutoff: the reference value depends on the reagent and analyzer your laboratory uses. As an adult reference point:

Parameter	Indicative reference value	Unit
CA 15-3 — adult	under ~30 (labs vary ~25–35)	U/mL (= µg/L)

Good to know: the usual unit is U/mL, equivalent to µg/L, so there is no conversion between U.S. and international reports. The "normal" threshold often sits between 25 and 35 U/mL depending on the test kit — the range printed on your report is what counts, not a figure seen online.⁴⁵ In monitoring, what matters is less the isolated value than its change over time, ideally compared across tests run in the same laboratory.⁶

What is CA 15-3?

CA 15-3 (cancer antigen 15-3) is a circulating fragment of MUC1, a large mucin protein on the surface of many cells — including the cells of the breast (mammary) gland. When certain cells, cancerous or not, become numerous or "stressed," they release more of this fragment into the blood, and the CA 15-3 level rises.¹⁰

This is the key point: CA 15-3 is not specific to cancer. The same MUC1 protein sits on healthy cells and appears in several benign conditions. CA 15-3 is therefore a signal, not proof. It has meaning only in context — in someone already being treated for breast cancer, watched as a trend over time, and read alongside imaging. Found in isolation on a broad panel, it diagnoses nothing by itself.

A monitoring marker, not a screening test. A tumor marker helps follow a known disease — to see whether it is shrinking, stable, or progressing. It is not a tool to "look for cancer" in a healthy person: breast cancer screening rests on mammography, not on CA 15-3.⁶²

What the CA 15-3 test is used for

A tumor marker is a substance, often a protein, that can be higher when cancer is present but also in benign conditions — so it is used to help follow a known cancer, not to find one.¹¹ Your physician may order CA 15-3 in specific situations, almost always around breast cancer:

to monitor an already-diagnosed advanced or metastatic breast cancer, and help judge whether treatment is working (the marker falls, holds steady, or rises);⁷⁸
sometimes to help flag a possible recurrence after treatment — but only together with the clinical exam and imaging, never on its own;⁶
occasionally to help work up a specific situation chosen by the specialist.

By contrast, CA 15-3 is not recommended to screen the general population for breast cancer, nor to make a diagnosis: its sensitivity and specificity are not good enough for that.¹⁶ If it turned up "by chance" on a wide panel, that is not a reason to panic — it is a number to put back in context with your doctor.

Interpreting your results

High CA 15-3

A high CA 15-3 is an unsettling result, but it should be read with care. Several situations can explain it:⁴⁵

a known advanced or metastatic breast cancer, where the marker is used for monitoring — not to "discover" the disease;⁷⁸
benign causes: some benign breast conditions, liver disease (hepatitis, cirrhosis), pregnancy or lactation, benign ovarian conditions, and some inflammatory states;⁴⁵
cancers other than breast — for example ovarian, lung, or pancreatic — can also raise CA 15-3: it is not specific to one organ.⁵

Two ideas are worth holding onto. First, a modest elevation — say, slightly above the threshold — is frequently benign and does not mean cancer. Second, the higher the value, the more it warrants medical review — but even a high number does not make the diagnosis. It is the imaging, the clinical exam, and the trend that decide.²

There is no magic cutoff at which a value "becomes cancer." A CA 15-3 just above the range is often benign or not meaningful; very high values point more toward active disease — usually metastatic, in someone already under care — but context rules. The same number means different things in a healthy person and in a patient on treatment. What guides the physician is above all the trend — is the marker climbing across several tests? — far more than a single value.⁶⁸

A normal CA 15-3 does not rule out cancer

This is the other side of the coin. CA 15-3 has low sensitivity in early, localized breast cancer: many real cancers run with a normal CA 15-3, and sensitivity rises only in advanced or metastatic disease.⁸⁹ In other words, you cannot be reassured by a normal CA 15-3, and you cannot "screen yourself" with it. Breast cancer screening relies on mammography and clinical follow-up, not on this marker.⁶²

CA 15-3 is not a screening or diagnostic test

This deserves to be stated plainly, because it is the single most common misunderstanding. Professional guidance in the United States — from the American Society of Clinical Oncology (ASCO) — does not recommend CA 15-3 to screen for breast cancer, nor to routinely surveil patients treated for early-stage disease.¹⁶ Its established role is in metastatic breast cancer, where it can be one input among several for tracking how the disease responds to therapy.⁷

The reasons are concrete. CA 15-3 misses many early cancers (low sensitivity) and rises in plenty of non-cancer conditions (limited specificity). Using it as a screen would generate both false reassurance and false alarms, driving anxiety and unnecessary tests. A raised CA 15-3 is a prompt to look, in context — not a verdict. If yours is elevated and you have no known cancer, that is not an emergency and not a diagnosis: your doctor will decide whether to recheck it and will look for benign explanations first.

Benign causes of a high CA 15-3

Because CA 15-3 comes from MUC1 — present on many healthy and inflamed tissues — a number of non-cancer conditions can nudge it up:⁴⁵

Benign breast disease — fibrocystic and other benign breast conditions.
Liver disease — hepatitis and especially cirrhosis can raise CA 15-3; if you have a known liver condition, tell your doctor, as it changes interpretation. (For the liver, see the ALT test.)
Pregnancy and lactation — normal physiological states that can lift the marker.
Benign ovarian conditions and some inflammatory states.
Other cancers — ovarian, lung, or pancreatic tumors can raise CA 15-3, since it is not organ-specific.⁵

The practical takeaways: a mild elevation is often benign, and the trend over time is more informative than any single reading. Mention a pregnancy, a known liver condition, or a benign breast problem to your clinician — each shifts how the result should be read.

CA 15-3 in breast cancer monitoring

Where CA 15-3 genuinely earns its place is in following advanced or metastatic breast cancer. Here it is used as one signal among several to sense the direction of the disease: a marker that falls suggests the treatment is working; one that is stable suggests control; one that rises can be an early hint of progression — always confirmed by imaging before any change in care.⁷⁶¹²

Two rules make this useful rather than misleading. First, compare like with like: ideally test in the same laboratory with the same assay, because values are not always interchangeable between analyzers.⁵⁶ Second, watch the trajectory, not the dot: a one-off wobble does not, by itself, change treatment — it is a consistent, confirmed rise or fall across several measurements that carries weight.⁶⁸ In early-stage disease treated with curative intent, routine CA 15-3 monitoring is not recommended, precisely because it does not improve outcomes and can cause needless worry.⁶

What can raise CA 15-3 (besides breast cancer)

Several things can move CA 15-3 without any breast cancer: liver disease, pregnancy or lactation, some benign breast conditions, inflammatory states, other cancers (ovarian, lung, pancreatic), and the laboratory technique itself — values are not always comparable from one analyzer to another.⁴⁵⁹ This is why, in monitoring, the marker is best measured in the same lab and judged by its change over time rather than a lone figure.⁶ Flag any pregnancy, known liver disease, or benign breast condition to your physician, because each one alters the interpretation.

Recent research

According to recent PubMed publications and clinical-trial registries:

Toward finer tools than CA 15-3. A landmark study in the New England Journal of Medicine showed that circulating tumor DNA (ctDNA) tracks the ups and downs of metastatic breast cancer earlier and more precisely than CA 15-3, pointing toward more sensitive monitoring tools.¹³ (Dawson SJ et al., 2013.)
Do markers need routine checking after treatment? A European trial is comparing regular CEA and CA 15-3 testing — with imaging triggered only by a marked rise — against usual follow-up, to see whether it detects recurrence sooner without overburdening patients.¹⁴
MUC1 as a therapeutic target. Because CA 15-3 derives from MUC1, research is actively exploring strategies that target MUC1 (including the MUC1-C oncoprotein) for both diagnosis and treatment of breast cancer — a promising but still largely experimental field.¹⁰

These findings concern monitoring and research; they do not authorize self-medication and do not replace your physician's advice.

Get your CA 15-3 interpreted by AI DiagMe

A CA 15-3 is never read alone: its meaning depends on your context (following a known cancer versus a stray panel result), the trend over time, and the imaging and clinical exam — because the same number can be benign in one person and meaningful in another. A high CA 15-3 does not equal cancer, and a normal one is not reassurance by itself. That cross-referencing is what gives the result its real value.

👉 AI DiagMe interprets your lab results — blood, urine, or stool — in plain language, taking your whole profile into account. An informational service that does not provide a diagnosis and complements, never replaces, your physician.

Frequently asked questions

What is a normal CA 15-3 level?

Indicatively under about 30 U/mL, though the threshold varies by lab (often 25–35 U/mL). U/mL and µg/L are the same unit. Trust the range printed on your report, and compare tests done in the same laboratory.⁴⁵

What does a high CA 15-3 mean?

Not necessarily cancer. A raised value — especially a mild one — can come from benign causes (benign breast disease, liver disease, pregnancy or lactation) or from cancers other than breast. CA 15-3 does not diagnose cancer: only the exam, imaging, and your physician's judgment can conclude.⁴²

Is CA 15-3 a screening test for breast cancer?

No. U.S. guidance (ASCO) does not recommend CA 15-3 for screening or diagnosis — it is neither sensitive nor specific enough. Its role is in monitoring already-known, mainly metastatic disease. Screening rests on mammography.¹⁶

Can benign conditions raise CA 15-3?

Yes — chiefly liver disease (hepatitis, cirrhosis), some benign breast conditions, pregnancy and lactation, benign ovarian conditions, and inflammatory states. Mention these to your doctor so the result is read correctly.⁴⁵

Is a mildly high CA 15-3 always cancer?

No. A value just above the range is often benign or not meaningful. There is no cutoff that flips from safe to cancer. What matters most is the trend across several tests and the full clinical picture, not a single number.⁶⁸

How is CA 15-3 used during breast cancer treatment?

As one signal to track advanced disease: a falling marker suggests response, a rising one can hint at progression — always confirmed by imaging. Your oncologist interprets these changes; a lone fluctuation does not, by itself, change treatment.⁷⁶

Bottom line

The CA 15-3 blood test measures cancer antigen 15-3, a tumor marker tied mainly to breast cancer and useful for monitoring advanced or metastatic disease — not for screening or diagnosis. Keep the order of magnitude in mind (under ~30 U/mL, lab-dependent), and above all two truths: a high CA 15-3 is not a cancer diagnosis (benign causes include liver disease, benign breast conditions, and pregnancy), and a normal CA 15-3 does not rule cancer out. There is no magic threshold — it is the trend, the imaging, and the clinical exam, interpreted by your physician, that count. CA 15-3 is just one tumor marker among several — CA 19-9 for pancreatic and GI cancers, CEA for colorectal cancer, CA-125 for ovarian cancer, AFP for liver and testicular cancers, and beta-hCG — all sharing one rule: they monitor and guide, not diagnose. Inflammation can move some of these numbers too (see CRP). No value is read alone: it is the full picture that gives it meaning — which is what AI DiagMe provides, alongside your physician.

Sources

Official sources and peer-reviewed publications (PubMed, ClinicalTrials.gov) used for this guide:

Harris L, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol, 2007. PubMed · DOI ↩ ↩² ↩³ ↩⁴ ↩⁵
National Cancer Institute (NIH) — Tumor Markers in Common Use. cancer.gov ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶
American Cancer Society — Understanding Your Lab Test Results / Tumor Markers. cancer.org ↩
Testing.com — CA 15-3 (Cancer Antigen 15-3). testing.com ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰
Dolscheid-Pommerich RC, et al. Clinical Performance of CEA, CA19-9, CA15-3, CA125 and AFP in Gastrointestinal Cancer Using LOCI-based Assays. Anticancer Res, 2017. PubMed · DOI ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹²
Khatcheressian JL, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol, 2013. PubMed · DOI ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴ ↩¹⁵ ↩¹⁶ ↩¹⁷
Van Poznak C, et al. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol, 2015. PubMed · DOI ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶
Molina R, et al. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat, 1998. PubMed · DOI ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷
Giovanella L, et al. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA). Clin Chem Lab Med, 2002. PubMed · DOI ↩ ↩² ↩³
Kufe DW. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene, 2013. PubMed · DOI ↩ ↩²
MedlinePlus (U.S. National Library of Medicine, NIH) — Tumor Marker Tests. medlineplus.gov ↩
Cleveland Clinic — Tumor Marker Tests. my.clevelandclinic.org ↩
Dawson SJ, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med, 2013. PubMed · DOI ↩
ClinicalTrials.gov — Follow-up of Early Breast Cancer by Dynamic Evaluation of CEA and CA 15.3 Followed by 18FDG-PET. Identifier NCT02261389. clinicaltrials.gov ↩